H.C. Wainwright Reiterates Buy Rating on EyePoint Pharmaceuticals, Inc. (EYPT)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $22.00 price target on EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT).

The analyst commented: "Earlier this week, EyePoint Pharmaceuticals announced that enrollment and randomization in the LUGANO trial has exceeded the target of 400 subjects. LUGANO is the first of two pivotal non-inferiority trials underway in the Phase 3 program of DURAVYU (vorolanib intravitreal insert, aka EYP-1901) for the treatment of wet AMD. Management expects to report topline data from LUGANO in mid-2026. In our view, the rapid pace of enrollment denotes enthusiasm among the wet AMD community for a treatment option with 6-month redosing. Looking forward to enrollment completion of the LUCIA trial, we reiterate our Buy rating and $22 price target."

For an analyst ratings summary and ratings history on EyePoint Pharmaceuticals, Inc. click here. For more ratings news on EyePoint Pharmaceuticals, Inc. click here.

Shares of EyePoint Pharmaceuticals, Inc. closed at $7.21 yesterday.

You May Also Be Interested In

• EyePoint Pharmaceuticals settles False Claims Act case for $4.7M
• Energy Vault Holdings (NRGV) files $300M mixed shelf
• Uber (UBER) Reiterated at Market Outperform by Citizens on Delivery Hero Deal